• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/1/24 8:06:10 AM ET
    $AHG
    $ATNF
    $BFRG
    $ERNA
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Kiora Pharmaceuticals (NASDAQ:KPRX) stock rose 48.3% to $0.82 during Thursday's pre-market session. The company's market cap stands at $6.2 million.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) stock rose 25.68% to $0.69. The market value of their outstanding shares is at $2.7 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) shares rose 20.59% to $0.75. The market value of their outstanding shares is at $74.1 million.
    • Eterna Therapeutics (NASDAQ:ERNA) stock rose 19.16% to $1.99. The market value of their outstanding shares is at $10.7 million.
    • Akso Health Group (NASDAQ:AHG) shares rose 18.9% to $1.95. The company's market cap stands at $44.5 million.
    • OpGen (NASDAQ:OPGN) stock rose 18.03% to $0.4. The market value of their outstanding shares is at $4.0 million.

    Losers

    • Revelation Biosciences (NASDAQ:REVB) stock decreased by 59.7% to $3.55 during Thursday's pre-market session.
    • OneMedNet (NASDAQ:ONMD) shares fell 24.34% to $1.43. The company's market cap stands at $46.1 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) shares fell 20.09% to $3.9. The market value of their outstanding shares is at $23.7 million.
    • Jin Medical International (NASDAQ:ZJYL) stock decreased by 18.83% to $214.5. The market value of their outstanding shares is at $1.6 billion.
    • Trinity Biotech (NASDAQ:TRIB) shares fell 14.56% to $0.5. The market value of their outstanding shares is at $19.2 million. The company's, Q3 earnings came out yesterday.
    • 180 Life Sciences (NASDAQ:ATNF) stock declined by 12.15% to $0.19. The company's market cap stands at $1.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $ATNF
    $BFRG
    $ERNA

    CompanyDatePrice TargetRatingAnalyst
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    12/2/2022Neutral → Underperform
    BofA Securities
    Salarius Pharmaceuticals Inc.
    $SLRX
    3/11/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    HOOKIPA Pharma Inc.
    $HOOK
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    Revelation Biosciences Inc.
    $REVB
    2/17/2022$12.00Buy
    Roth Capital
    HOOKIPA Pharma Inc.
    $HOOK
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    Kiora Pharmaceuticals Inc.
    $KPRX
    1/19/2022$2.50Buy
    Maxim Group
    More analyst ratings

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

    MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generati

    2/27/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet's portfolio of high-value specialty datasets and supporting resea

    2/26/26 8:40:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Roper Jess covered exercise/tax liability with 1,591 shares, decreasing direct ownership by 11% to 12,828 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:31:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chawla Lakhmir S covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 16% to 12,158 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:30:45 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by BofA Securities

    BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

    12/2/22 12:03:07 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Ernexa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

    2/26/26 4:31:18 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:25:26 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Leadership Updates

    Live Leadership Updates

    View All

    Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

    CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

    12/2/25 8:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

    DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director. Mr. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors. He currently serves as Chief Financial Officer of Deriva Energy LLC, one of the largest independent renewable power producers in the United States and a Brookfield portfolio company. His previous

    8/21/25 9:00:23 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

    - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreement ("SEPA") with an affiliate of financing partner Yorkville Advisors Global ("Yorkville"). The agreement provides Trinity Biotech with an additional funding tool designed to augment th

    2/25/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

    DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares ("MVPHS") of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nas

    2/20/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

    DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on

    2/13/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AHG
    $ATNF
    $BFRG
    $ERNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care